Stay updated with breaking news from Eoe Endoscopic Reference Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data. “Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active
Eosinophilic Esophagitis MarketThe global demand for Eosinophilic Esophagitis Market is projected to increase at a CAGR of 28% during the forecast period between 2023 and 2033, reaching a total of US$ 2,032.8 Billion by 2033, according to a report from Future Market Insights (FMI). From 2018 to 2023, sales witnessed...
The European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to treat eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates ...
As BMI increases in patients with EoE, the odds of histologic, symptomatic, and endoscopic response to topical corticosteroids decreases.
Body weight has emerged as a potential clinical predictor of reduced symptomatic, endoscopic, and histologic response to topical steroid therapy in patients with eosinophilic esophagitis.